Peptide Telehealth Provider Directory
Directory of U.S. telehealth peptide providers with verified pricing, pharmacy disclosure and clinician oversight.
No peptide telehealth provider receives a blanket “best” award without product-level evidence
Directory of U.S. telehealth peptide providers with verified pricing, pharmacy disclosure and clinician oversight.
Peptide programs can combine FDA-approved medicines, patient-specific compounded prescriptions, investigational substances and products marketed only for research. Peptides Editorial therefore evaluates each provider at the product and facility level rather than converting a broad catalog into a single promotional score.
Minimum evidence required for ranking
| Domain | Evidence expected | Editorial use |
|---|---|---|
| Clinical identity | Named prescribing practice and licensed clinician | Required before a provider can be ranked |
| Product status | FDA-approved, compounded, investigational or research-only | Categories are not treated as interchangeable |
| Pharmacy or manufacturer | Legal entity and facility-level evidence | Needed for medication-sourcing transparency |
| Human evidence | Product-specific trials and studied route/dose | Mechanism alone does not establish benefit |
| Price and terms | Recurring total, mandatory fees and commitment | Introductory prices are separated from ongoing cost |
How to use this directory
Start with the specific substance, indication and route. Confirm whether a licensed clinician is prescribing it, whether the product is FDA approved for that use, and which legal entity manufactures or compounds it. A provider is not elevated because it offers more substances or makes stronger longevity claims.
Until a complete normalized record is available, the publication may describe a provider but will not invent a price, safety score or “best” designation. This avoids turning missing evidence into a favorable assumption.
Current editorial position
For obesity treatment, the GLP-1 provider database contains sufficiently structured pricing and clinical evidence for normalized comparisons. For many non-GLP-1 peptide programs, evidence remains product-specific and less standardized. Readers should use the peptide evidence pages to evaluate each substance before comparing vendors.
Operational standard
This policy is applied through a claim-level evidence ledger. Each material claim records the source, capture date, evidence class, reviewer and the pages that reuse it. Centralizing the record prevents a price or regulatory fact from being updated on one page while remaining stale elsewhere.
Pages are reviewed on a scheduled cadence and whenever a material trigger occurs: an FDA approval or warning, label change, new pivotal trial, shortage-status change, manufacturer pricing update, provider fee change, pharmacy disclosure change or substantiated correction. Cosmetic edits do not reset a clinical-review date.
Peptides Editorial distinguishes three forms of certainty. Verified means the current primary source directly supports the statement. Provider-reported means the company states the fact but additional facility, checkout or third-party confirmation may still be needed. Not normalized means the available evidence is insufficient for a comparative claim; the site does not fill the gap with an estimate.
Publication safeguards
- One visible H1 and one canonical URL per page.
- Answer-first summaries retain material qualifications, not just the favorable number.
- Medical efficacy is never inferred from a provider price, testimonial or receptor description.
- Compounded, investigational and FDA-approved products are labeled as different regulatory categories.
- Prices display the commitment, mandatory fees and evidence date in the same comparison context.
- Reviewer credentials and roles are stated narrowly; unsupported degrees, affiliations or licenses are not published.
- Corrections that alter rankings trigger recalculation across every dependent page.
Frequently asked questions
How are factual claims approved?
Claims are checked against the highest available source tier. Regulatory and safety statements use FDA records or official labeling; clinical-outcome statements use peer-reviewed primary research; prices use provider or manufacturer terms with a capture date.
Can a provider review or correct its page?
A provider may submit primary evidence and a written response. Editorial staff verifies the evidence and corrects material errors, but the provider does not approve the conclusion or buy a score.
Does medical review make this personal medical advice?
No. Medical review improves factual and clinical accuracy but does not evaluate an individual reader, create a clinician-patient relationship or replace emergency care.
How is AI used?
Automation may help organize source ledgers, detect inconsistencies and draft structured summaries. Final published claims, tables and conclusions remain subject to human editorial review and the same evidence standard.